Minor phytocannabinoid

CBNRCannabinerol

(Z) isomer of cannabigerol, studied since 2022 on neuronal cells only.

Harm-reduction warning

No characterised human dose: animal / in vitro data only. Effect profile, safety margin and acute toxicity are not documented in human clinical practice. Extremely potent compound: severe effects, seizures and deaths reported in the literature.

Receptors and activity

CB1Modulator15 out of 100
activation suggérée par transcriptomique sur cellules NSC-34 ; aucune constante d'affinité publiée
CB2Modulatoraucune constante d'affinité publiée5 out of 100

Bar length shows the relative strength of the interaction, as an indication.

Subjective signature

Calm: 6 out of 100; Relaxation of body and mind; reduced mental noise without marked drowsiness.
Clarity: 4 out of 100; Sustained attention and clear thinking; functional lucidity, not euphoria.
High: 2 out of 100; Euphoria and sensory intensity; altered perception of time and space.
Appetite: 4 out of 100; Stimulation of hunger and of taste appreciation (the “munchies” effect).
Sleep: 4 out of 100; Sedative effect: aids sleep onset and the continuity of deep sleep.

Editorial estimate, not clinical.

Pharmacology

Cannabinerol (CBNR) is the (Z) isomer of cannabigerol: its terpene chain is of the neryl type instead of geranyl. Long overlooked, it has been the subject since 2022 of transcriptomic work by a team in Messina. In the NSC-34 line, the expression profile suggests activation of the CB1 receptor and of the kinase Akt between 20 and 7.5 µM, with a rise in Neurod1 and Map2 pointing to early neuronal differentiation; a 2024 study describes the regulation of synaptic genes, including subunits of calcium, sodium and potassium channels. In a cellular model of Alzheimer's disease, pretreatment limited the loss of viability induced by the β-amyloid peptide. These results remain preliminary: no binding affinity, no animal data and no human data have been published.

Key sources.

History

Source: Described in recent literature as a little-known phytocannabinoid of Cannabis sativa L. It is the geometric isomer of cannabigerol: the terpene chain is of the neryl type (Z double bond) instead of geranyl (E double bond).

Biosynthetic pathway

Biosynthetic pathway: cannabinerol is the analogue of cannabigerol in which the resorcinol is alkylated by a neryl unit rather than a geranyl one. Its acid form would be cannabinerolic acid, an isomer of cannabigerolic acid. The share of this pathway in the plant is not quantified in the sources consulted.

Legal framework

European Union: No control measure of its own at European Union level. The molecule appears in no schedule of the 1961 Convention on Narcotic Drugs or of the 1971 Convention on Psychotropic Substances. It holds no marketing authorisation and no novel food authorisation under Regulation (EU) 2015/2283: it circulates only as a chemical or reference standard intended for research.
France: Unscheduled substance. Cannabinerol is named in no annex of the order of 22 February 1990 and falls under no generic clause. It is not a tetrahydrocannabinol and does not derive from the benzo[c]chromene nucleus targeted by the ANSM decision of 22 May 2024: its skeleton is that of cannabigerol, a resorcinol carrying an open terpene chain, with no pyran ring.

Sources: EUR-Lex, UNODC, CND, ANSM, IUPHAR/BPS, ChEBI, EUDA. Our method.

References

Structured data

SMILES: CCCCCC1=CC(=C(C(=C1)O)C/C=C(/C)\CCC=C(C)C)O
InChIKey: QXACEHWTBCFNSA-ATVHPVEESA-N

Machine-readable entry (JSON)

LLM ingestion format: a structured superset of the entry (identifiers, binding, versioned legal status). Full corpus.